Article Text

PDF
Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy
  1. S Flores Moreno1,
  2. J Bautista Paloma2
  1. 1
    Andalusian Agency for Health Technology Assessment, Seville, Spain
  2. 2
    Virgen del Rocío Hospital, Seville, Spain
  1. Dr S Flores Moreno, Andalusian Agency for Health Technology Assessment, Zafra street, n°1 Seville, 41006 Spain; sandra.flores.sspa{at}juntadeandalucia.es

Statistics from Altmetric.com

The use of intravitreal Bevacizumab had been considered a first-line therapy in age-related macular degeneration (AMD) treatment until 2 years ago, despite the fact that there were no clinical trials backing it and that Bevacizumab was not created for that purpose. Consequently, Genentech modified the molecule of Bevacizumab, without affecting the basis of its efficacy but with the specific aim of treating this pathology, and so the new drug Ranibizumab was developed. However, no indirect comparisons have revealed any significant differences between both treatments in efficacy.13

The …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Mailbox
    C Liu J Olney